Albuminar-20 Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Albuminar-20 market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the increasing prevalence of hypovolemia, a rise in liver diseases, a growing number of surgical procedures, the expansion of critical care applications, and the increasing population of dialysis patients.

The anticipated growth in the forecast period is driven by the rising incidence of burns and trauma, an aging population, greater adoption across various therapeutic areas, a high prevalence of protein deficiencies, and growing awareness of albumin-based treatments. Key trends during this period include product innovations, advancements in biotechnology, strategic collaborations and partnerships, and market growth in emerging regions.

The growing demand for biological products is expected to accelerate the expansion of the albuminar-20 market in the future. Biological products are complex pharmaceutical substances derived from living organisms, used for diagnosing, preventing, treating, and curing medical conditions. The rising demand for biological products is driven by factors such as environmental concerns, increased consumer awareness, and the need for sustainable, effective alternatives to synthetic chemicals. Biologics enable the production of albuminar-20 by utilizing advanced biotechnology, such as recombinant DNA technology, to introduce the human serum albumin gene into host cells, which then produce the protein in large quantities for medical applications. For example, in October 2024, the US Food and Drug Administration reported that by the end of 2022, 40 biosimilars had been approved, with 27 available in the United States. As a result, the growing demand for biological products is propelling the growth of the albuminar-20 market.

The rise in healthcare expenditure is expected to drive the growth of the albuminar-20 market in the coming years. Healthcare expenditure refers to the total financial resources spent on healthcare services, including medical treatment, hospital services, pharmaceuticals, medical equipment, public health programs, and administrative costs. Factors such as aging populations, medical technology advancements, a higher prevalence of chronic diseases, and increased demand for quality healthcare services contribute to the rise in healthcare spending. This increase in spending supports albuminar-20 by facilitating greater access to advanced therapies, improving healthcare infrastructure, and boosting demand for plasma-derived products, especially in regions with aging populations and a higher incidence of chronic diseases. For instance, in September 2024, the Centers for Medicare & Medicaid Services reported that US healthcare spending increased by 4.1% in 2022, totaling $4.5 trillion, or $13,493 per capita. Therefore, the rise in healthcare expenditure is driving the growth of the albuminar-20 market.

The growth in surgical procedures is expected to further fuel the expansion of the albuminar-20 market. Surgical procedures are medical operations performed to diagnose, treat, or manage health conditions through manual or instrumental techniques. The increase in surgical procedures is driven by factors such as advancements in medical technology, rising chronic disease prevalence, aging populations, and growing demand for minimally invasive techniques. Albuminar-20 plays a key role in surgical procedures by acting as a plasma volume expander, stabilizing blood pressure, maintaining circulatory volume, and supporting organ function during or after surgery, particularly in cases involving significant blood loss or trauma. For instance, in September 2023, the International Society of Aesthetic Plastic Surgery reported an 11.2% increase in procedures performed by plastic surgeons in 2022, with over 14.9 million surgical and 18.8 million non-surgical procedures performed worldwide. Additionally, both surgical and non-surgical procedures showed increases compared to previous surveys. Therefore, the rise in surgical procedures will contribute to the growth of the albuminar-20 market.

The key company operating in the albuminar-20 market is Grifols SA.

North America was the largest region in the albuminar-20 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in albuminar-20 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the albuminar-20 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Albuminar-20 is a sterile 20% human serum albumin solution used as a plasma volume expander and for various therapeutic purposes. It works by maintaining oncotic pressure, which helps restore and stabilize blood volume in conditions such as hypovolemia, burns, or hypoalbuminemia. Derived from pooled human plasma and processed to minimize the risk of infectious agents, Albuminar-20 is primarily utilized in critical care environments.

The primary formulations in the albuminar-20 market include human serum albumin, recombinant albumin, and bovine serum albumin. Human serum albumin (HSA) is a protein found in human blood plasma that plays an essential role in maintaining oncotic pressure (which keeps fluid within blood vessels) and transporting substances such as hormones, fatty acids, and drugs. Common indications for use include shock treatment, burns, and hypoalbuminemia, with distribution channels including hospitals, clinics, and retail and specialty pharmacies. The main end users of albuminar-20 are hospitals and clinics, the pharmaceutical and biotechnology industry, and research institutes.

The albuminar-20 market research report is one of a series of new reports that provides albuminar-20 market statistics, including albuminar-20 industry global market size, regional shares, competitors with a albuminar-20 market share, detailed albuminar-20 market segments, market trends, and opportunities, and any further data you may need to thrive in the albuminar-20 industry. This albuminar-20 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The albuminar-20 market consists of sales of human serum albumin solutions and protein replacement or plasma volume expansion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.